Arcus Biosciences Inc (RCUS)
Debt-to-equity ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 462,000 | 520,000 | 566,000 | 600,000 | 657,000 | 699,000 | 747,000 | 797,000 | 842,000 | 542,607 | 604,555 | 664,790 | 502,000 | 544,417 | 428,710 | 140,638 | 164,000 | 177,227 | 196,646 | 221,567 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $462,000K
= 0.00
Based on the provided data, Arcus Biosciences Inc has consistently maintained a debt-to-equity ratio of 0.00 across all quarters from Q1 2022 to Q4 2023. This indicates that the company does not have any debt on its balance sheet relative to its equity during these periods. A debt-to-equity ratio of 0.00 suggests that the company is not relying on debt financing to fund its operations or growth, and it may indicate a conservative financial management approach. It's important to note that while a low or zero debt-to-equity ratio can be favorable in terms of financial stability and risk, it may also mean missed opportunities for leveraging debt for potential growth or expansion. Overall, Arcus Biosciences Inc's consistent zero debt-to-equity ratio reflects a strong financial position with a minimal reliance on debt as a source of capital.
Peer comparison
Dec 31, 2023